|
|
 |
|
Viewing report
|
|
|
|
Commercial and Pipeline Insight: Allergic Rhinitis
Datamonitor, Oct 2007, Pages: 319
The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products.
These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.
Scope
- Indication-based forecasts for allergic rhinitis products and significant pipeline drugs
- Assessment of country-specific drivers and resistors likely to impact the market
- Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates
- Assessment of the remaining unmet clinical needs in allergic rhinitis, analyzing the potential of new targeted therapies
Highlights
The allergic rhinitis market was worth about $10 billion in 2006 and has been decreasing in value over the last few years due to patent expiries and limited levels of innovation. The top 2 drug classes prescribed for the treatment of allergic rhinitisoral antihistamines and nasal corticosteroids accounted for 77% of the total sales in this market.
At least 3 major allergic rhinitis players have developed and launched an oral antihistamine/decongestant fixed dose combination. However, several practical concerns have limited the use of these treatments and none of the products have reached sales as high as their single antihistamine component.
The immunotherapy market is moving from a niche position towards baseline therapy. We expect a sublingual tablet for the treatment of grass allergy (such as Grazax) to be able to reach annual sales of $780m to $1.3 billion, depending on the patient population targeted, the length of administration and price of the product.
Reasons to Purchase
- Identify key opportunities and threats that will impact the use and uptake of new and existing products
- Quantify the future size and scope of the allergic rhinitis market and predict the future performance of key compounds
- Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development
Customers who bought this item also bought
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
Strategic Perspectives: Allergic Rhinitis - Impact of a blockbuster going bust
Allergic Conjunctivitis: A Specialized Market
Drugs of Tomorrow 2000: Allergic Rhinitis - New Drug Classes, Towards Total Disease Management
Market Dynamics 2000: Allergic Rhinitis: Effects of Major Patent Expiries On An Expanding Market
Rigels Allergic Rhinitis Candidate - R112
Treatment Algorithms 2001: Allergic Rhinitis - Unlocking the Real Patient Potential
|
|
|
|
